Clinical Trial Update: DNA-guided Second Line Adjuvant Therapy for High Residual Risk, Estrogen Receptor Positive, HER-2 Negative Breast Cancer (DARE) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating DNA-guided second-line adjuvant therapy for high residual risk, estrogen receptor–positive, HER2-negative breast cancer is cur…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Snippet

Sponsor: Criterium, Inc. | Conditions: Breast Cancer | Phase 2 | Status: RECRUITING